Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS).

Bordigoni P, Faure G, Bene MC, Dardenne M, Bach JF, Duheille J, Olive D

Lancet (London, England)1 Aug 1982Cited by 40 (Europe PMC)

PMID6124716DOI10.1016/s0140-6736(82)90271-9PepBankPUB-06124716

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanCase report or seriesEfficacy outcome
In immunodeficient children receiving synthetic FTS, infection frequency decreased.
In plain wordsIn immunodeficient children, infections became less frequent during FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseInfection frequency
Study
n = 3
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
A reduction in frequency and severity of infection was noted concomitantly with improvement in cell-mediated-immunity tests.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471601
02HumanCase report or seriesEfficacy outcome
In immunodeficient children receiving synthetic FTS, infection severity decreased.
In plain wordsIn immunodeficient children, infections became less severe during FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseInfection severity
Study
n = 3
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
A reduction in frequency and severity of infection was noted concomitantly with improvement in cell-mediated-immunity tests.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471602
03HumanCase report or seriesEfficacy outcome
In immunodeficient children receiving synthetic FTS, cell-mediated immunity test results improved.
In plain wordsIn immunodeficient children, cellular immunity tests improved during FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseCell-mediated immunity tests
Study
n = 3
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
A reduction in frequency and severity of infection was noted concomitantly with improvement in cell-mediated-immunity tests.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471603
04HumanCase report or seriesEfficacy outcome
In immunodeficient children receiving FTS, vaccination antigen-specific antibodies appeared for the first time or reached previously unattained titres.
In plain wordsIn immunodeficient children, vaccine-specific antibodies appeared or reached previously unattained levels during FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseVaccination antigen-specific antibodies
Study
n = 3
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Specific antibodies against vaccination antigens appeared for the first time or increased to titres higher than ever before.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471606
05HumanCase report or seriesEfficacy outcome
In two immunodeficient children receiving FTS, previously absent serum IgA appeared within 4 weeks.
In plain wordsIn two immunodeficient children, previously absent IgA appeared within 4 weeks of FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseAppearance of serum IgA
Study
n = 2
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Serum IgA, which was absent in two patients, appeared within 4 weeks of treatment and increased significantly in the third patient.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471604
06HumanCase report or seriesEfficacy outcome
In two immunodeficient children, immune improvement regressed after FTS interruption and returned after treatment resumed.
In plain wordsIn two immunodeficient children, immune improvement regressed when FTS stopped and returned when treatment resumed.
Peptide
Thymulin (serum thymic factor)
Outcome
MixedImmune improvement during interruption and resumption
Study
n = 2
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
In two patients, transient interruption of FTS administration was followed by a regression of the immunological improvement, but this disappeared after the treatment was started again.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471607
07HumanCase report or seriesEfficacy outcome
In the third immunodeficient child receiving FTS, serum IgA increased significantly.
In plain wordsIn the third immunodeficient child, IgA increased significantly during FTS treatment.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseIncrease in serum IgA
Study
n = 1
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Serum IgA, which was absent in two patients, appeared within 4 weeks of treatment and increased significantly in the third patient.
1 context sentence(design, population, supporting numbers)
Summary · context
Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously.
Report a problemFND-0612471605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.